These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22297735)

  • 1. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.
    Frenzel K; Ganepola S; Michel D; Thiel E; Krüger DH; Uharek L; Hofmann J
    Med Microbiol Immunol; 2012 Aug; 201(3):277-86. PubMed ID: 22297735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.
    Aiba N; Shiraki A; Yajima M; Oyama Y; Yoshida Y; Ohno A; Yamada H; Takemoto M; Daikoku T; Shiraki K
    Viral Immunol; 2017 Sep; 30(7):500-507. PubMed ID: 28598267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: Impact of CMV IgG normalization.
    Schampera MS; Schweinzer K; Abele H; Kagan KO; Klein R; Rettig I; Jahn G; Hamprecht K
    J Clin Virol; 2017 May; 90():40-45. PubMed ID: 28342316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmission of cell-associated human cytomegalovirus isolates between various cell types using polymorphonuclear leukocytes as a vehicle.
    Braun B; Sinzger C
    Med Microbiol Immunol; 2021 Aug; 210(4):197-209. PubMed ID: 34091753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convallatoxin-Induced Reduction of Methionine Import Effectively Inhibits Human Cytomegalovirus Infection and Replication.
    Cohen T; Williams JD; Opperman TJ; Sanchez R; Lurain NS; Tortorella D
    J Virol; 2016 Dec; 90(23):10715-10727. PubMed ID: 27654292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Cytomegalovirus Replication and Infection-Induced Syncytia Formation in Labial, Foreskin, and Fetal Lung Fibroblasts.
    Aguiar A; Galinato M; Bradley Silva M; Toth B; McVoy MA; Hertel L
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of
    Jackson JW; Hancock TJ; Dogra P; Patel R; Arav-Boger R; Williams AD; Kennel SJ; Wall JS; Sparer TE
    mSphere; 2019 Feb; 4(1):. PubMed ID: 30760613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
    Planitzer CB; Saemann MD; Gajek H; Farcet MR; Kreil TR
    Transplantation; 2011 Aug; 92(3):267-70. PubMed ID: 21659947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins.
    Miescher SM; Huber TM; Kühne M; Lieby P; Snydman DR; Vensak JL; Berger M
    Vox Sang; 2015 Jul; 109(1):71-8. PubMed ID: 25766313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients.
    Ramirez-Avila L; Garner OB; Cherry JD
    Pediatr Transplant; 2014 Sep; 18(6):599-601. PubMed ID: 25041939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
    Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
    Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Humoral Response Against Epithelial Cell Entry-Mediated Infection in the Primary Infection Setting After Hematopoietic Cell Transplantation.
    Zamora D; Krantz EM; Green ML; Joncas-Schronce L; Blazevic R; Edmison BC; Huang ML; Stevens-Ayers T; Jerome KR; Geballe AP; Boeckh M
    J Infect Dis; 2020 Apr; 221(9):1470-1479. PubMed ID: 31734696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus prophylaxis by intravenous immunoglobulins in five heart transplanted patients.
    Tinelli M; Percivalle E; Zambelli A; Grossi P; Maccabruni A
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):459-67. PubMed ID: 1967092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.
    Cui X; Freed DC; Wang D; Qiu P; Li F; Fu TM; Kauvar LM; McVoy MA
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28381568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of active cytomegalovirus infection by analysis of immediate-early, early and late transcripts in peripheral blood cells of immunodeficient patients.
    Meyer T; Reischl U; Wolf H; Schüller C; Arndt R
    Mol Cell Probes; 1994 Aug; 8(4):261-71. PubMed ID: 7870068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Properties of Human Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin Preparations.
    Germer M; Herbener P; Schüttrumpf J
    Ann Transplant; 2016 Sep; 21():558-64. PubMed ID: 27595792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.